Yamada Norie, Murayama Asako, Shiina Masaaki, Aly Hussein Hassan, Iwamoto Masashi, Tsukuda Senko, Watashi Koichi, Tanaka Tomohisa, Moriishi Kohji, Nishitsuji Hironori, Sugiyama Masaya, Mizokami Masashi, Shimotohno Kunitada, Muramatsu Masamichi, Murata Kazumoto, Kato Takanobu
Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Department of Gastroenterology and Hepatology, Shin-Yurigaoka General Hospital, Kawasaki, Japan.
Hepatol Res. 2020 Mar;50(3):283-291. doi: 10.1111/hepr.13449. Epub 2020 Jan 5.
Interferon (IFN)-λ3 is known to have antiviral effects against various pathogens. Recently, it has been reported that the production of IFN-λ3 in colon cells after the administration of nucleotide analogs is expected to reduce hepatitis B surface antigen in chronic hepatitis B patients. Here, we aimed to prove the antiviral effects of IFN-λ3 on hepatitis B virus (HBV) by using an in vitro HBV production and infection system.
We used HepG2.2.15-derived HBV as an inoculum and the replication-competent molecular clone of HBV as a replication model.
By administering IFN-λ3 to HepG2 cells transfected with the HBV molecular clone, the production of hepatitis B surface antigen and hepatitis B core-related antigen was reduced dose-dependently. IFN-λ3 treatment also reduced the number of HBV-positive cells and the synthesis of covalently closed circular DNA after infection of HepG2.2.15-derived HBV to sodium taurocholate cotransporting polypeptide-transduced HepG2 cells. The inhibitory effect on HBV infection by IFN-λ3 was confirmed by using a recombinant a HBV reporter virus system. To elucidate the underlying mechanisms of the anti-HBV effect of IFN-λ3, we assessed the transcription of HBV RNA and the production of core-associated HBV DNA in HBV molecular clone-transfected HepG2 cells, and found that both parameters were reduced by IFN-λ3.
We observed that the administration of IFN-λ3 inhibits HBV infection and the production of HBV proteins at the HBV RNA transcription level. This finding provides novel insight into the treatment of chronic hepatitis B patients with the administration or induction of IFN-λ3.
已知干扰素(IFN)-λ3 对多种病原体具有抗病毒作用。最近,有报道称在慢性乙型肝炎患者中给予核苷酸类似物后结肠细胞中 IFN-λ3 的产生有望降低乙肝表面抗原。在此,我们旨在通过使用体外乙肝病毒(HBV)产生和感染系统来证明 IFN-λ3 对 HBV 的抗病毒作用。
我们使用源自 HepG2.2.15 的 HBV 作为接种物,并使用具有复制能力的 HBV 分子克隆作为复制模型。
通过将 IFN-λ3 给予转染了 HBV 分子克隆的 HepG2 细胞,乙肝表面抗原和乙肝核心相关抗原的产生呈剂量依赖性降低。IFN-λ3 处理还减少了源自 HepG2.2.15 的 HBV 感染牛磺胆酸钠共转运多肽转导的 HepG2 细胞后 HBV 阳性细胞的数量以及共价闭合环状 DNA 的合成。通过使用重组α乙肝报告病毒系统证实了 IFN-λ3 对 HBV 感染的抑制作用。为了阐明 IFN-λ3 抗 HBV 作用的潜在机制,我们评估了转染 HBV 分子克隆的 HepG2 细胞中 HBV RNA 的转录以及核心相关 HBV DNA 的产生,发现这两个参数均被 IFN-λ3 降低。
我们观察到给予 IFN-λ3 在 HBV RNA 转录水平抑制 HBV 感染和 HBV 蛋白的产生。这一发现为使用 IFN-λ3 治疗慢性乙型肝炎患者提供了新的见解。